${\bf (19)}\ World\ Intellectual\ Property\ Organization$

International Bureau





(43) International Publication Date 13 July 2006 (13.07.2006) (10) International Publication Number WO 2006/073496 A3

(51) International Patent Classification:

C12N 15/864 (2006.01) A61P 31/00 (2006.01) A61K 39/21 (2006.01) A61P 37/00 (2006.01)

(21) International Application Number:

PCT/US2005/027091

(22) International Filing Date: 29 July 2005 (29.07.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/592,889 30 July 2004 (30.07.2004) US

(71) Applicants (for all designated States except US): TAR-GETED GENETICS CORPORATION [US/US]; 1100 Olive Way, Suite 100, Seattle, Washington 98101 (US). CHILDREN'S HOSPITAL, INC. [US/US]; 700 Children's Drive, Columbus, Ohio 43205 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): PELUSO, Richard [US/US]; 454 Northern Parkway, Ridgewood, New Jersey 07450 (US). ARNOLD, Susan [US/US]; 8100 Frankford Avenue, Philadelphia, Pennsylvania 19136 (US). WUSTNER, Jason [US/US]; 12 Sunset Drive, Paoli, Pennsylvania 19301 (US). JOHNSON, Philip, R. [US/US]; 206 Indian Creek Road, Winwood, Pennsylvania 19096 (US). SCHULTZ, Alan, M. [US/US]; 9431 Quill Place, Gaithersburg, Maryland 20886 (US). STEPAN, Anthony, M. [US/US]; 3211 41st Avenue, S.W., Seattle, Washington 98110 (US).

- (74) Agents: ZHOU, Jie et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 3 May 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: RECOMBINANT AAV BASED VACCINE METHODS

(57) Abstract: The present invention relates to recombinant adeno-associated virus (rAAV) based materials and methods for eliciting an immune response to a pathogen. The present invention provides vector sets comprising a priming vector and a boosting vector, wherein at least one of the vectors in the vector set is a rAAV vector, and methods for eliciting a prophylactic immune response in a mammalian subject susceptible to infection by a pathogen, such as for example, an RNA virus, including HIV-1, and methods for eliciting a therapeutic immune response in a mammalian subject infected by a pathogen that has progressed to a disease state associated with the pathogen, such as for example, an RNA virus, including HIV-1. In particular, the present invention provides methods for eliciting an enhanced boost immune response in a mammalian subject susceptible to infection by or infected by a pathogen.



International application No PCT/US2005/027091

a. classification of subject matter INV. C12N15/864 A61K39/21

C. DOCUMENTS CONSIDERED TO BE RELEVANT

A61P31/00

A61P37/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Category*

Minimum documentation searched (classification system followed by classification symbols)

C12N A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBASE, MEDLINE, SCISEARCH, PAJ

Citation of document, with indication, where appropriate, of the relevant passages

X	XIN KE-QIN ET AL: "A novel reco adeno-associated virus vaccine i long-term humoral immune respons immunodeficiency virus" HUMAN GENE THERAPY, vol. 12, no. 9, 10 June 2001 (20 pages 1047-1061, XP002395739 ISSN: 1043-0342 the whole document	nduces a e to human	1-34
* Special ca *A' documer conside *E' earlier dr filing da *L' documer which is citation *O' documer other m *P' documer later tha	nt which may throw doubts on priority claim(s) or s cited to establish the publication date of another or other special reason (as specified) nt referring to an oral disclosure, use, exhibition or	"T" later document published after the interest or priority date and not in conflict with cited to understand the principle or the invention "X" document of particular relevance; the cannot be considered novel or cannot involve an inventive step when the document of particular relevance; the cannot be considered to involve an in document is combined with one or ments, such combination being obvious the art. "&" document member of the same patent Date of mailing of the international sea	the application but early underlying the claimed invention be considered to current is taken alone claimed invention ventive step when the ore other such docuus to a person skilled

14/03/2007

Domingues, Helena

Authorized officer

Name and mailing address of the ISA/

11 January 2007

Ruropean Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016 Relevant to claim No.

International application No
PCT/US2005/027091

C(Continua	tion). DOCUMENTS CONSIDERED TO BE RELEVANT	101/032005/02/091
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	PEDEN CARMEN S ET AL: "Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain" JOURNAL OF VIROLOGY, vol. 78, no. 12, June 2004 (2004-06), pages 6344-6359, XP002395740 ISSN: 0022-538X the whole document	1-34
Y	HALBERT C L ET AL: "Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes" JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 74, no. 3, February 2000 (2000-02), pages 1524-1532, XP002242061 ISSN: 0022-538X the whole document	1-34
Y	WO 03/042397 A (THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA; GAO, GUANGPING; WILSON) 22 May 2003 (2003-05-22) pages 45-46 examples 1-10	1-34
Y	WO 01/68888 A (NEUROLOGIX, INC) 20 September 2001 (2001-09-20) example 1	1-34
Y	JOHNSON PHILIP R ET AL: "Pre-clinical evaluation of a novel HIV vaccine based on an adeno-associated virus vector." PEDIATRIC RESEARCH, vol. 53, no. 4 Part 2, April 2003 (2003-04), page 334A, XP009071316 & ANNUAL MEETING OF THE PEDIATRIC ACADEMIC SOCIETIES'; SEATTLE, WA, USA; MAY 03-06, 2003 ISSN: 0031-3998 the whole document -/	1-34

3

International application No PCT/US2005/027091

C(Continua	tion). DOCUMENTS CONSIDERED TO BE RELEVANT	
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Υ	CLARK K REED ET AL: "A single dose, adeno-associated virus vector SIV vaccine elicits long-lived immune responses in macaques" JOURNAL OF MEDICAL PRIMATOLOGY, vol. 29, no. 3-4, August 2000 (2000-08), pages 290-291, XP009071318 & 17TH ANNUAL SYMPOSIUM ON NONHUMAN PRIMATE MODELS FOR AIDS; NEW ORLEANS, LOUISIANA, USA; OCTOBER 06-09, 1999 ISSN: 0047-2565 the whole document	1-34
Υ	SHIVER J W ET AL: "RECENT ADVANCES IN THE DEVELOPMENT OF HIV-1 VACCINES USING REPLICATION-INCOMPETENT ADENOVIRUS VECTORS" ANNUAL REVIEW OF MEDICINE: SELECTED TOPICS IN THE CLINICAL SCIENCES, ANNUAL REVIEWS INC., PALO ALTO, CA, US, vol. 55, 10 December 2003 (2003-12-10), pages 355-372, XP009058216 ISSN: 0066-4219 the whole document	1-34
Y	NEWMAN M J: "HETEROLOGOUS PRIME-BOOST VACCINATION STRATEGIES FOR HIV-1: AUGMENTING CELLULAR IMMUNE RESPONSES" CURRENT OPINION IN INVESTIGATIONAL DRUGS, PHARMAPRESS, US, vol. 3, no. 3, March 2002 (2002-03), pages 374-378, XP009037697 ISSN: 1472-4472 the whole document	1-34
Y	RAMA RAO AMARA ET AL: "CONTROL OF A MUCOSAL CHALLENGE AND PREVENTION OF AIDS BY A MULTIPROTEIN DNA/MVA VACCINE" SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 292, no. 5514, 6 April 2001 (2001-04-06), pages 69-74, XP000986110 ISSN: 0036-8075 the whole document	1-34
Y	WO 99/43843 A (UNIV JOHNS HOPKINS MED [US]; HE TONG CHUAN [US]; VOGELSTEIN BERT [US];) 2 September 1999 (1999-09-02) page 3, lines 15-26 page 7, lines 18-27 page 9, lines 27-30 page 12, lines 3-13 page 14, lines 17-31	35-125
	_/	

International application No
PCT/US2005/027091

	ttion). DOCUMENTS CONSIDERED TO BE RELEVANT	<u> </u>	
ategory*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No	
Y	LICHTENSTEIN D L ET AL: "FUNCTIONS AND MECHANISMS OF ACTION OF THE ADENOVIRUS E3 PROTEINS" INTERNATIONAL REVIEWS OF IMMUNOLOGY, HARWOOD ACADEMIC PUBLISHERS, US, vol. 23, no. 1/2, January 2004 (2004-01), pages 75-111, XP009071853 ISSN: 0883-0185 page 100, paragraph 2	35-125	
Y	TOLLEFSON ANN E ET AL: "The Ed3-11.6-kDa adenovirus death protein (ADP) is required for efficient cell death: Characterization of cells infected with adp mutants" VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 220, no. 1, 1996, pages 152-162, XP002162708 ISSN: 0042-6822 pages 154-155 figures 2,3	35-125	
Y	DORONIN K ET AL: "Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein" JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 74, no. 13, July 2000 (2000-07), pages 6147-6155, XP002162706 ISSN: 0022-538X page 6151	35-125	
Y	DORONIN KONSTANTIN ET AL: "Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus." VIROLOGY, vol. 305, no. 2, 20 January 2003 (2003-01-20), pages 378-387, XP002414301 ISSN: 0042-6822 page 381	35-125	
E	WO 2006/078279 A (THE TRUSTEES OF THE UNIVERSITY OF PENNYLVANIA; WILSON, JAMES, M) 27 July 2006 (2006-07-27) example 2	1-34	

International application No PCT/US2005/027091

C(Continua	tion). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	
Х,Р	JOHNSON PHILIP R ET AL: "Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques" JOURNAL OF VIROLOGY, vol. 79, no. 2, January 2005 (2005-01), pages 955-965, XP002395741 ISSN: 0022-538X the whole document	1-34	
X,P	GALLEZ-HAWKINS G ET AL: "DNA and low titer, helper-free, recombinant AAV prime-boost vaccination for cytomegalovirus induces an immune response to CMV-pp65 and CMV-IE1 in transgenic HLA A*0201 mice" VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 23, no. 6, 21 December 2004 (2004-12-21), pages 819-826, XP004637089 ISSN: 0264-410X the whole document	1-34	

3

International application No. PCT/US2005/027091

INTERNATIONAL SEARCH REPORT

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: — because they relate to subject matter not required to be searched by this Authority, namely:
Although claims $1\!-\!17$ are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
1. X As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest. X No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-34

Concern aspects related to a method for eliciting a boost immune response to a pathogen in a mammalian subject susceptible to infection by or infected by the pathogen comprising the administration of a boost dose of an antigen of a pathogen, particularly of an RNA viral pathogen, by a recombinant vector to a mammalian subject having previously received a prime dose of said antigen by a recombinant vector; wherein at least the prime dose or the boost dose are administered by a recombinant adeno-associated virus (rAAV) vector, with the proviso that when both the prime and boost dose are administered by rAAV, they are not both administered by AAV2.

2. claims: 35-125

Concern aspects related to methods for generating a recombinant adenoviral vector or particle using a linear DNA molecule and a supercoiled adenoviral vector comprising an adenoviral genome with one or more deletions, particularly an E3 deletion, but encoding a functional E3 adenoviral death protein; and to kits comprising two plasmids that can be used to obtain recombinant adenoviral vectors.

Information on patent family members

International application No
PCT/US2005/027091

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 03042397	Α	22-05-2003	AT	317916 T	15-03-2006
			BR	0214119 A	28-06-2005
			CA	2406745 A1	13-05-2003
		-	CA	2465868 A1	22-05-2003
			DE	60209193 T2	28-09-2006
			DK	1310571 T3	19-06-2006
			EP	1310571 A2	14-05-2003
			EP	1456419 A2	15-09-2004
			ES	2258601 T3	01-09-2006
			HK	1056198 A1	16-06-2006
			JP	2003235562 A	26-08-2003
			JP	2005525086 T	25-08-2005
			KR	20050058234 A	16-06-2005
			MX	PA04004600 A	13-08-2004
WO 0168888	_ _	20-09-2001	AU	4565401 A	24-09-2001
			CA	2373110 A1	20-09-2001
			EP	1228234 A2	07-08-2002
			JP	2003526377 T	09-09-2003
WO 9943843		02-09-1999	AU	747847 B2	23-05-2002
			AU	2787599 A	15-09-1999
			CA	2322066 A1	02-09-1999
			EP	1056881 A1	06-12-2000
			US	5922576 A	13-07-1999
WO 2006078279	_ <u>_</u>	27-07-2006	CA	2563538 A1	27-07-2006